These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Diabetic macular oedema in 2011: what are the options for refractory cystic oedema? Wickremasinghe S Clin Exp Ophthalmol; 2011; 39(7):595-7. PubMed ID: 22452678 [No Abstract] [Full Text] [Related]
10. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Kumar V; Ghosh B; Raina UK; Goel N Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427 [No Abstract] [Full Text] [Related]
11. Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema. Kim HD; Kang KD; Choi KS; Rhee MR; Lee SJ Acta Ophthalmol; 2014 Nov; 92(7):e589-90. PubMed ID: 24866832 [No Abstract] [Full Text] [Related]
12. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions. O'Malley PG Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778 [No Abstract] [Full Text] [Related]
17. Antivascular endothelial growth factor in diabetic retinopathy. Iacono P; Battaglia Parodi M; Bandello F Dev Ophthalmol; 2010; 46():39-53. PubMed ID: 20703031 [TBL] [Abstract][Full Text] [Related]
18. Diabetic macular edema. Lang GE Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for macular edema secondary to retinal macroaneurysm. Chanana B; Azad RV Eye (Lond); 2009 Feb; 23(2):493-4. PubMed ID: 18388958 [No Abstract] [Full Text] [Related]
20. Refining the treatment parameters of diabetic retinopathy: new prospects and limitations on the horizon. Ziemssen F; Spital G J Diabetes Complications; 2014; 28(2):119. PubMed ID: 24360342 [No Abstract] [Full Text] [Related] [Next] [New Search]